Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size

Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01189201
First received: August 25, 2010
Last updated: October 4, 2012
Last verified: October 2012
History of Changes
  Purpose

The primary objective of the current study is to investigate the relative bioavailability of BI 10773 / linagliptin fixed dose combination tablet (formulation A1, Treatment A, Test) compared to BI 10773 given in free combination with linagliptin (Treatment B, Reference), both in the fasting state. All 42 subjects entered are planned to be included in this comparison.

The secondary objective is to investigate the relative bioavailability of BI 10773 / linagliptin fixed dose combination tablet after administration of a standardised high fat, high caloric meal (formulation A1, Treatment C, Test) compared to BI 10773 / linagliptin fixed dose combination in the fasting state (formulation A1,Treatment A, Reference). Of the 42 subjects entered 18 subjects are planned to be included in this comparison.

An additional objective is to investigate the relative bioavailability of a second formulation of the fixed dose combination tablet of BI 10773 / linagliptin (formulation A3,Treatment D, Test) compared to BI 10773 / linagliptin fixed dose combination tablet (formulation A1,Treatment A, Reference). Of the 42 subjects entered 24 subjects are planned to be included in this comparison.


Condition Intervention Phase
Healthy
 Drug: BI 10773/linagliptin
Drug: BI 10773/linagliptin SID
Drug: BI 10773/linagliptin FDC
 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-availability Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Relative Bioavailability Investigations of a 25 mg BI 10773 / 5 mg Linagliptin Fixed Dose Combination (FDC) Tablet (Formulation A1) Including the Comparison With Its Mono-components, the Comparison With a Second FDC Tablet (Formulation A3), and the Investigation of Food (an Open-label, Randomised, Single Dose, Crossover, Phase I Trial in Healthy Male and Female Volunteers)

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • maximum measured concentration of the analyte in plasma for BI 10773 and linagliptin [ Time Frame: 4 days ] [ Designated as safety issue: No ]
  • area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 72 hours for linagliptin [ Time Frame: 4 days ] [ Designated as safety issue: No ]
  • area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable drug plasma concentration for BI 10773 [ Time Frame: 4 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • time from last dosing to the maximum measured concentration of each analyte in plasma for BI 10773 and linagliptin [ Time Frame: 4 days ] [ Designated as safety issue: No ]
  • area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for BI 10773 and linagliptin [ Time Frame: 4 days ] [ Designated as safety issue: No ]
  • Additional pharmacokinetic parameters will be calculated as appropriate [ Time Frame: 4 days ] [ Designated as safety issue: No ]
  • Physical examination [ Time Frame: 2 days ] [ Designated as safety issue: Yes ]
  • Vital signs (blood pressure, pulse rate) [ Time Frame: 2 days ] [ Designated as safety issue: Yes ]
  • 12-lead electrocardiogram [ Time Frame: 2 days ] [ Designated as safety issue: Yes ]
  • Clinical laboratory tests (haematology, clinical chemistry and urinalysis) [ Time Frame: 3 days ] [ Designated as safety issue: Yes ]
  • Adverse events [ Time Frame: 5 days ] [ Designated as safety issue: Yes ]
  • Assessment of tolerability by investigator [ Time Frame: 5 days ] [ Designated as safety issue: Yes ]
Enrollment: 42
Study Start Date: August 2010
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BI 10773/linagliptin FDC SID
medium single dose ofBI 10773/linagliptin FDC (Formulation A1)
 Drug: BI 10773/linagliptin
medium single dose of BI 10773/linagliptin FDC (Formulation A1)
Experimental: BI 10773/linagliptin SID
medium single dose of mono components BI 10773/linagliptin
 Drug: BI 10773/linagliptin SID
medium single dose of mono components BI 10773/linagliptin
Experimental: BI 10773/linagliptin FDC
medium single dose of BI 10773/linagliptin FDC (Formulation A1) after high fat, high caloric meal
 Drug: BI 10773/linagliptin FDC
medium single dose of BI 10773/linagliptin FDC (Formulation A1) after high fat, high caloric meal
Experimental: BI 10773/linagliptin
medium single dose of BI 10773/linagliptin FDC (Formulation A3)
 Drug: BI 10773/linagliptin
medium single dose of BI 10773/linagliptin FDC (Formulation A3)

  Eligibility
Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria:

healthy male and female subjects

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01189201

Locations
Germany
1275.3.1 Boehringer Ingelheim Investigational Site
Biberach, Germany
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

No publications provided

Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT01189201     History of Changes
Other Study ID Numbers: 1275.3, 2010-019211-38
Study First Received: August 25, 2010
Last Updated: October 4, 2012
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:
Linagliptin
Dipeptidyl-Peptidase IV Inhibitors
Enzyme Inhibitors
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Hypoglycemic Agents
 Incretins
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors

ClinicalTrials.gov processed this record on March 03, 2015